NASDAQ:HARP

Harpoon Therapeutics Stock Forecast, Price & News

$20.72

-0.20 (-0.96 %)

(As of 01/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$20.30

Now: $20.72▼

$21.15

50-Day Range

$12.83

MA: $18.23▼

$24.16

52-Week Range

$10.27

Now: $20.72▼

$25.24

Volume115,098 shs

Average Volume386,029 shs

Market Capitalization$525.87 million

P/E RatioN/A

Dividend YieldN/A

Beta0.87

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536, which is in Phase I/IIa clinical trial for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Overall MarketRank^™

1.49 out of 5 stars

Medical Sector

428th out of 1,925 stocks

Biological Products, Except Diagnostic Industry

55th out of 177 stocks

3.5 Analyst's Opinion

Consensus Rating
Harpoon Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $31.50, Harpoon Therapeutics has a forecasted upside of 52.0% from its current price of $20.72.
Amount of Analyst Coverage
Harpoon Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.3 Community Rank

Outperform Votes
Harpoon Therapeutics has received 61 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Harpoon Therapeutics has received 70 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Harpoon Therapeutics has received 53.44% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Harpoon Therapeutics and other stocks. Vote “Outperform” if you believe HARP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HARP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Harpoon Therapeutics does not currently pay a dividend.
Dividend Growth
Harpoon Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Harpoon Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,145,539.00 in company stock.
Percentage Held by Insiders
Only 34.90% of the stock of Harpoon Therapeutics is held by insiders.
Percentage Held by Institutions
79.03% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Harpoon Therapeutics are expected to decrease in the coming year, from ($2.12) to ($2.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Harpoon Therapeutics is -9.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Harpoon Therapeutics is -9.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Harpoon Therapeutics has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HARP

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.harpoontx.com

Phone650-443-7400

Employees77

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio3.49

Quick Ratio3.49

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.78 million

Price / Sales90.98

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.82 per share

Price / Book5.42

Profitability

EPS (Most Recent Fiscal Year)($2.55)

Net Income$-55,570,000.00

Net Margins-434.74%

Return on Equity-68.32%

Return on Assets-29.45%

Miscellaneous

Outstanding Shares25,380,000

Market Cap$525.87 million

Next Earnings Date3/11/2021 (Estimated)

OptionableNot Optionable

$20.72

-0.20 (-0.96 %)

(As of 01/26/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.

Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HARP shares have increased by 58.5% and is now trading at $20.72.
View which stocks have been most impacted by COVID-19.

Is Harpoon Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Harpoon Therapeutics stock.
View analyst ratings for Harpoon Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Harpoon Therapeutics?

Wall Street analysts have given Harpoon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Harpoon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO?

4 employees have rated Harpoon Therapeutics CEO Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among Harpoon Therapeutics' employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Harpoon Therapeutics.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its earnings results on Wednesday, November, 4th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.04. The firm earned $3.89 million during the quarter, compared to analyst estimates of $4.60 million. Harpoon Therapeutics had a negative net margin of 434.74% and a negative trailing twelve-month return on equity of 68.32%.
View Harpoon Therapeutics' earnings history.

What price target have analysts set for HARP?

8 equities research analysts have issued 1 year price targets for Harpoon Therapeutics' stock. Their forecasts range from $25.00 to $38.00. On average, they expect Harpoon Therapeutics' stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price.
View analysts' price targets for Harpoon Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Harpoon Therapeutics' key competitors?

Some companies that are related to Harpoon Therapeutics include NantKwest (NK), Bavarian Nordic A/S (BVNRY), Sangamo Therapeutics (SGMO), Scholar Rock (SRRK), Vericel (VCEL), Replimune Group (REPL), Translate Bio (TBIO), C4 Therapeutics (CCCC), BioCryst Pharmaceuticals (BCRX), Forma Therapeutics (FMTX), REGENXBIO (RGNX), Atara Biotherapeutics (ATRA), Coherus BioSciences (CHRS), Krystal Biotech (KRYS) and Alector (ALEC).
View all of HARP's competitors.

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:

Dr. Gerald McMahon, Pres, CEO & Director (Age 66, Pay $749.11k)
Ms. Georgia L. Erbez, Chief Financial Officer (Age 54, Pay $500.79k)
Dr. Natalie R. Sacks, Chief Medical Offer (Age 56, Pay $538.42k)
Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 53)
Ms. Rachael Lester, VP of Corp. Devel.
Dr. Susan Dana Jones Ph.D., Sr. VP of Product Devel.
Dr. Che-Leung Law Ph.D., Sr. VP of Translational Medicine
Mr. Christopher Whitmore, VP of Fin. & Sec.

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an IPO on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners acted as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $20.72.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $525.87 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 77 workers across the globe.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is www.harpoontx.com.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here